| Name | Title | Contact Details |
|---|
Purposeful Design is a Christian ministry that exists to help rebuild lives of individuals who have struggled with addiction, homelessness, incarceration and other obstacles; to equip them with valuable work skills; and to provide the gift of work (Genesis 2:15, Matthew 28:16-20, Ephesians 2:8-10).
Nobu, the world-renowned Japanese restaurant recognized for pioneering a new-style Japanese cuisine, started as a business partnership in 1994 between Chef Nobu Matsuhisa and his partners, Academy Award-winning actor Robert De Niro, producer Meir Teper, and restaurateur Drew Nieporent. Originating in New York as the flagship restaurant, the Nobu brand is now an empire that spans five continents with over 40 restaurants and growing. Following the success of the restaurants, Nobu Hospitality opened the first Nobu Hotel in 2013 in Las Vegas and today has 13 hotels open with several more in development.
88rising (stylized as 88⬆) is an American mass media company that founded in 2015 by Sean Miyashiro describes as a "hybrid management, record label, video production and marketing company." The company has gained popularity as a musical platform and label for Asian artists such as Keith Ape, Rich Brian, Joji, NIKI, and Higher Brothers. Headquartered in New York City, the company also has offices in Los Angeles and Shanghai. Outside of its core group, the company has collaborated with other artists such as Ghostface Killah, 21 Savage, XXXTentacion, Trippie Redd, Ski Mask the Slump God, Kris Wu, Yaeji, and others.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.